Business Description
![I-MAB I-MAB logo](https://static.gurufocus.com/logos/0C0000BQ51.png?14)
I-MAB
ISIN : US44975P1030
Share Class Description:
IMAB: ADRDescription
I-Mab Biopharma is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 17.07 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | -0.09 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -4.8 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -76.1 | |||||
3-Year Book Growth Rate | -37.1 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 42.19 | |||||
9-Day RSI | 38.31 | |||||
14-Day RSI | 39.02 | |||||
6-1 Month Momentum % | -10.8 | |||||
12-1 Month Momentum % | -33.33 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.67 | |||||
Quick Ratio | 5.67 | |||||
Cash Ratio | 5.55 | |||||
Days Sales Outstanding | 7.18 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4 | |||||
Shareholder Yield % | -1.29 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -4422.33 | |||||
Net Margin % | -5304.17 | |||||
FCF Margin % | -2073.6 | |||||
ROE % | -61.51 | |||||
ROA % | -42.68 | |||||
ROIC % | -269.14 | |||||
ROC (Joel Greenblatt) % | -1406.27 | |||||
ROCE % | -52.01 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 34.78 | |||||
PB Ratio | 0.54 | |||||
Price-to-Tangible-Book | 0.58 | |||||
EV-to-EBIT | 0.84 | |||||
EV-to-Forward-EBIT | -0.01 | |||||
EV-to-EBITDA | 0.84 | |||||
EV-to-Forward-EBITDA | -0.01 | |||||
EV-to-Revenue | -44.47 | |||||
EV-to-Forward-Revenue | 0.23 | |||||
EV-to-FCF | 2.14 | |||||
Price-to-Net-Current-Asset-Value | 0.64 | |||||
Price-to-Net-Cash | 0.66 | |||||
Earnings Yield (Greenblatt) % | 119.05 | |||||
FCF Yield % | -61.92 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IMAB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
I-MAB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 3.864 | ||
EPS (TTM) ($) | -2.464 | ||
Beta | 1.03 | ||
Volatility % | 54.46 | ||
14-Day RSI | 39.02 | ||
14-Day ATR ($) | 0.08506 | ||
20-Day SMA ($) | 1.739 | ||
12-1 Month Momentum % | -33.33 | ||
52-Week Range ($) | 1.16 - 3.17 | ||
Shares Outstanding (Mil) | 80.88 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
I-MAB Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
I-MAB Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
I-MAB Frequently Asked Questions
What is I-MAB(IMAB)'s stock price today?
The current price of IMAB is $1.60. The 52 week high of IMAB is $3.17 and 52 week low is $1.16.
When is next earnings date of I-MAB(IMAB)?
The next earnings date of I-MAB(IMAB) is 2024-08-16 Est..
Does I-MAB(IMAB) pay dividends? If so, how much?
I-MAB(IMAB) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |